Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lian-Hua Qing-Ke Tablets for severe COVID-19 pneumonia
ChiCTR2100042068Phase 4Recruiting
- Sponsor
- Hebei Province Chest Hospital
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Lianhua Qingke in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Province Chest Hospital. Primary endpoints: Time to clinical improvement by Day 28 and Clinical improvement rate by Day 28. Started Jan 2021; status: recruiting.
02
Drugs
Lianhua Qingke
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100042068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042068.